Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller, Paul D; Hattersley, Gary; Riis, Bente Juel; Williams, Gregory C; Lau, Edith; Russo, Luis Augusto; Alexandersen, Peter; Zerbini, Cristiano A F; Hu, Ming-yi; Harris, Alan G; Fitzpatrick, Lorraine A; Cosman, Felicia; Christiansen, Claus.
; 316(7): 722-33, 2016 Aug 16.
Artigo em Inglês | MEDLINE | ID: mdl-27533157
Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
New anabolic therapies for osteoporosis.
Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
Abaloparatide for the treatment of postmenopausal osteoporosis.
Emerging anabolic agents in the treatment of osteoporosis.
Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments.
Mechanisms of vasodilation to PTH 1-84, PTH 1-34, and PTHrP 1-34 in rat bone resistance arteries.
A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.